MA40605A - Composé pyrazolothiazole et médicament - Google Patents

Composé pyrazolothiazole et médicament

Info

Publication number
MA40605A
MA40605A MA040605A MA40605A MA40605A MA 40605 A MA40605 A MA 40605A MA 040605 A MA040605 A MA 040605A MA 40605 A MA40605 A MA 40605A MA 40605 A MA40605 A MA 40605A
Authority
MA
Morocco
Prior art keywords
present
jak1
medication
compounds
compound
Prior art date
Application number
MA040605A
Other languages
English (en)
Other versions
MA40605B1 (fr
Inventor
Satoshi Akiyama
Yoshinobu Shiba
Original Assignee
Nippon Shinyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Shinyaku Co Ltd filed Critical Nippon Shinyaku Co Ltd
Publication of MA40605A publication Critical patent/MA40605A/fr
Publication of MA40605B1 publication Critical patent/MA40605B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/25—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids with polyoxyalkylated alcohols, e.g. esters of polyethylene glycol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

L'objectif de la présente invention est de fournir un composé ayant un effet inhibiteur exceptionnel de jak1. Des exemples de la présente invention comprennent des composés pyrazolothiazole représentés par la formule générale [i], ainsi que des sels pharmaceutiquement acceptables de ceux-ci. Les composés de la présente invention ont une activité inhibitrice de jak1. étant donné cette activité inhibitrice jak1, les composés de la présente invention ont également un effet immunosuppresseur (contre, par exem
MA40605A 2014-09-02 2015-09-02 Composé pyrazolothiazole et médicament MA40605B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014177969 2014-09-02
PCT/JP2015/074935 WO2016035814A1 (fr) 2014-09-02 2015-09-02 Composé pyrazolothiazole et médicament

Publications (2)

Publication Number Publication Date
MA40605A true MA40605A (fr) 2017-07-12
MA40605B1 MA40605B1 (fr) 2020-10-28

Family

ID=55439874

Family Applications (1)

Application Number Title Priority Date Filing Date
MA40605A MA40605B1 (fr) 2014-09-02 2015-09-02 Composé pyrazolothiazole et médicament

Country Status (34)

Country Link
US (2) US9937176B2 (fr)
EP (1) EP3190116B1 (fr)
JP (1) JP6558372B2 (fr)
KR (1) KR102294330B1 (fr)
CN (1) CN107108653B (fr)
AU (1) AU2015312886B2 (fr)
BR (1) BR112017003800B1 (fr)
CA (1) CA2959721C (fr)
CL (1) CL2017000478A1 (fr)
CO (1) CO2017002982A2 (fr)
CY (1) CY1123320T1 (fr)
DK (1) DK3190116T3 (fr)
ES (1) ES2827243T3 (fr)
HR (1) HRP20201382T1 (fr)
HU (1) HUE050565T2 (fr)
IL (1) IL250729B (fr)
LT (1) LT3190116T (fr)
MA (1) MA40605B1 (fr)
MX (1) MX377926B (fr)
MY (1) MY181814A (fr)
NZ (1) NZ729494A (fr)
PE (1) PE20170668A1 (fr)
PH (1) PH12017500383B1 (fr)
PL (1) PL3190116T3 (fr)
PT (1) PT3190116T (fr)
RS (1) RS60798B1 (fr)
RU (1) RU2688660C2 (fr)
SG (2) SG10201901676UA (fr)
SI (1) SI3190116T1 (fr)
SM (1) SMT202000503T1 (fr)
TW (1) TWI679205B (fr)
UA (1) UA121869C2 (fr)
WO (1) WO2016035814A1 (fr)
ZA (1) ZA201701492B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI679205B (zh) * 2014-09-02 2019-12-11 日商日本新藥股份有限公司 吡唑并噻唑化合物及醫藥
TWI712604B (zh) * 2016-03-01 2020-12-11 日商日本新藥股份有限公司 具jak抑制作用之化合物之結晶
DE112017007625B4 (de) 2017-06-09 2022-09-01 Mitsubishi Electric Corporation Passagierförderer
US20230117592A1 (en) * 2019-12-23 2023-04-20 Sri International Lipoxygenase inhibitors
WO2025216268A1 (fr) * 2024-04-09 2025-10-16 国立研究開発法人国立循環器病研究センター Agent prophylactique ou thérapeutique contre l'hypertension pulmonaire sévère ou une maladie du tissu conjonctif
JP7742516B1 (ja) * 2025-07-31 2025-09-19 日本新薬株式会社 好酸球性多発血管炎性肉芽腫症の処置剤

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3600390A1 (de) 1986-01-09 1987-07-16 Hoechst Ag Diarylalkyl-substituierte alkylamine, verfahren zu ihrer herstellung, ihre verwendung sowie sie enthaltende arzneimittel
PH25866A (en) * 1986-03-20 1991-12-02 Takeda Chemical Industries Ltd Sulfonylurea compounds and their herbicides
US5082847A (en) 1990-07-18 1992-01-21 Syntex (U.S.A.) Inc. Carbostyril compounds connected via an oxyalkyl group with a piperidine ring and having pharmaceutical utility
GB0216383D0 (en) 2002-07-13 2002-08-21 Astrazeneca Ab Compounds
DK1704145T3 (da) 2004-01-12 2012-09-24 Ym Biosciences Australia Pty Selektive kinaseinhibitorer
CA2563963A1 (fr) 2004-04-28 2005-11-10 Pfizer Inc. Derives 3-heterocyclyl-4-phenyl-triazole comme inhibiteurs de la vasopressine par recepteur
EP2532667A1 (fr) * 2005-09-30 2012-12-12 Vertex Pharmaceuticals Incorporated Déazapurines convenant comme inhibiteurs de janus kinases
NZ567851A (en) * 2005-11-01 2011-09-30 Targegen Inc Bi-aryl meta-pyrimidine inhibitors of kinases
AR060316A1 (es) 2006-01-17 2008-06-11 Vertex Pharma Azaindoles de utilidad como inhibidores de janus quinasas
PL2288610T3 (pl) 2008-03-11 2017-12-29 Incyte Holdings Corporation Azetydynowe i cyklobutanowe pochodne jako inhibitory jak
BRPI0911659B8 (pt) * 2008-04-15 2021-05-25 Eisai R&D Man Co Ltd composto 3-fenilpirazolo[5,1-b]tiazol e composição farmacêutica compreendendo o mesmo
JO3041B1 (ar) 2008-07-25 2016-09-05 Galapagos Nv مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية
ES2422263T3 (es) * 2008-12-19 2013-09-10 Nerviano Medical Sciences Srl Pirazoles bicíclicos como inhibidores de la proteinquinasa
TWI462920B (zh) 2009-06-26 2014-12-01 葛萊伯格有限公司 用於治療退化性及發炎疾病之新穎化合物
WO2011075334A1 (fr) 2009-12-18 2011-06-23 Pfizer Inc. Composés pyrrolo[2,3-d]pyrimidines
TW201124078A (en) 2009-12-22 2011-07-16 Du Pont Fungicidal 2-(bicyclic aryloxy) carboxamides
EP2338888A1 (fr) 2009-12-24 2011-06-29 Almirall, S.A. Dérivés d'imidazopyridine en tant qu'inhibiteurs JAK
JP2011136925A (ja) 2009-12-28 2011-07-14 Dainippon Sumitomo Pharma Co Ltd 含窒素二環性化合物
US8461328B2 (en) 2010-01-12 2013-06-11 Genentech, Inc. Tricyclic heterocyclic compounds, compositions and methods of use thereof
UY33213A (es) 2010-02-18 2011-09-30 Almirall Sa Derivados de pirazol como inhibidores de jak
ES2525581T3 (es) 2010-07-12 2014-12-26 Pfizer Limited Derivados de N-sulfonilbenzamida útiles como inhibidores del canal de sodio dependiente de voltaje
WO2012022045A1 (fr) 2010-08-20 2012-02-23 Hutchison Medipharma Limited Composés pyrrolopyrimidiniques et leurs utilisations
WO2012037132A1 (fr) 2010-09-14 2012-03-22 Exelixis, Inc. Dérivés de la phtalazine comme inhibiteurs de jak1
US8937077B2 (en) 2010-10-22 2015-01-20 Merck Sharp & Dohme Corp. Bicyclic diamines as janus kinase inhibitors
WO2012085176A1 (fr) 2010-12-23 2012-06-28 F. Hoffmann-La Roche Ag Composés pyrazinones tricycliques, leurs compositions et leurs procédés d'utilisation en tant qu'inhibiteurs de janus kinase
WO2013025628A1 (fr) * 2011-08-15 2013-02-21 Ligand Pharmaceuticals Incorporated Composés et procédés d'inhibition de janus kinase
TWI679205B (zh) * 2014-09-02 2019-12-11 日商日本新藥股份有限公司 吡唑并噻唑化合物及醫藥

Also Published As

Publication number Publication date
TWI679205B (zh) 2019-12-11
RU2688660C2 (ru) 2019-05-22
HRP20201382T1 (hr) 2020-11-27
MA40605B1 (fr) 2020-10-28
CY1123320T1 (el) 2021-12-31
CO2017002982A2 (es) 2017-07-11
PH12017500383B1 (en) 2019-11-20
JP6558372B2 (ja) 2019-08-14
PH12017500383A1 (en) 2017-07-17
ZA201701492B (en) 2022-05-25
CN107108653B (zh) 2019-04-09
PL3190116T3 (pl) 2020-11-30
PE20170668A1 (es) 2017-06-06
TW201613942A (en) 2016-04-16
SG11201701447UA (en) 2017-03-30
MX2017002488A (es) 2017-05-23
SMT202000503T1 (it) 2020-11-10
BR112017003800B1 (pt) 2022-09-13
BR112017003800A2 (pt) 2017-11-28
PT3190116T (pt) 2020-09-04
US9937176B2 (en) 2018-04-10
MY181814A (en) 2021-01-08
SI3190116T1 (sl) 2020-10-30
SG10201901676UA (en) 2019-03-28
EP3190116B1 (fr) 2020-08-05
WO2016035814A1 (fr) 2016-03-10
UA121869C2 (uk) 2020-08-10
JPWO2016035814A1 (ja) 2017-06-22
CA2959721A1 (fr) 2016-03-10
MX377926B (es) 2025-03-10
US20180092919A1 (en) 2018-04-05
IL250729B (en) 2019-09-26
AU2015312886A1 (en) 2017-03-16
LT3190116T (lt) 2020-11-10
HUE050565T2 (hu) 2020-12-28
US9999622B2 (en) 2018-06-19
KR102294330B1 (ko) 2021-08-25
CL2017000478A1 (es) 2017-11-10
CN107108653A (zh) 2017-08-29
KR20170044202A (ko) 2017-04-24
IL250729A0 (en) 2017-04-30
RU2017110535A3 (fr) 2018-10-31
ES2827243T3 (es) 2021-05-20
RS60798B1 (sr) 2020-10-30
US20170252341A1 (en) 2017-09-07
EP3190116A1 (fr) 2017-07-12
DK3190116T3 (da) 2020-09-07
EP3190116A4 (fr) 2018-04-04
CA2959721C (fr) 2022-10-25
AU2015312886B2 (en) 2020-02-06
RU2017110535A (ru) 2018-10-04
NZ729494A (en) 2022-04-29

Similar Documents

Publication Publication Date Title
MA40605A (fr) Composé pyrazolothiazole et médicament
PH12017502171A1 (en) PYRIDO[3,4-d]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
MA46337A (fr) Composé de pyridine
MA33330B1 (fr) Quinazolines substituées comme fongicides
SA520412335B1 (ar) مشتقات أوكسي فلورو ببريدين كمثبط كيناز
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
TN2020000125A1 (en) Amino-fluoropiperidine derivative as kinase inhibitor
MA38390A1 (fr) Composés tétrahydropyrrolothiazines
EA201891703A1 (ru) Соединения бензопиразола и их аналоги
MX2015006039A (es) Derivados de pirimidin-2, 4-diamina para el tratamiento de cancer.
MA34385B1 (fr) Composés hétérocycliques condensés comme inhibiteurs de phosphodiestérases (pdes)
MY196572A (en) Amino-Methyl Piperidine Derivative as Kinase Inhibitor
MA38583A1 (fr) Dérivés de dolastatine 10 et d'auristatines
MA39152B1 (fr) Cyclopentanes substitués en 1,2 utilisés comme antagonistes du récepteur d'orexine
SA519401827B1 (ar) [3، 4- d] مشتق بيريدو بيريميدين وملح مقبول صيدلانياً منه
BRPI0511433A (pt) derivados de quinolina substituìda como inibidores de cinesina mitótica
NZ746906A (en) Oxaborole esters and uses thereof
MA39315A1 (fr) Dérivés de pyridazine à utiliser dans la prévention ou le traitement d'un trouble ataxique
EA201692557A1 (ru) Хинолизиноновые производные в качестве ингибиторов pi3k
MX2019012640A (es) Metodos de uso de derivados de benzotriazoles trisustituidos como inhibidores de dihidroorotato-oxigenasa.
MA30664B1 (fr) Derive d'aminoalcool et immunodepresseur le contenant en tant que principe actif.
WO2020251871A3 (fr) Nouveaux composés de tétrahydroquinoléine substitués en tant qu'inhibiteurs de l'indoléamine 2,3-dioxygénase (ido)
EA201591369A1 (ru) Новые производные пиримидина в качестве ингибиторов фосфодиэстеразы 10 (pde-10)
WO2014062852A3 (fr) Dérivés de thiohydantoïnes et leurs utilisations
MA38991A1 (fr) Dérivés d'indole-urée substitués par un glucopyranosyle et leur utilisation à titre d'inhibiteurs de sglt